Phio Pharmaceuticals (PHIO) Other Accumulated Expenses (2011 - 2024)
Phio Pharmaceuticals' (PHIO) quarterly Other Accumulated Expenses came in at $17000.0 in Q4 2024, down 77.92% YoY from $77000.0 in Q1 2024, and down 77.92% on a QoQ basis from $77000.0 in Q4 2023.
Phio Pharmaceuticals (PHIO) Other Accumulated Expenses (2011 - 2024) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 12 years of Other Accumulated Expenses data on file, last reported at $17000.0 in Q4 2024.
- Quarterly Other Accumulated Expenses fell 77.92% year-over-year to $17000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $17000.0 (down 77.92% YoY) and the FY2024 annual result came in at $17000.0, down 77.92% from the prior year.
- Other Accumulated Expenses slipped to $17000.0 in Q4 2024, from $77000.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $104000.0 in Q4 2020 to a low of $17000.0 in Q4 2024.
- A 4-year average of $54250.0 and a median of $48000.0 in 2022 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Other Accumulated Expenses jumped 305.26% — and 2024, when it tumbled 77.92%.
- Tracing PHIO's Other Accumulated Expenses over 4 years: stood at $104000.0 in 2020, then plunged by 81.73% to $19000.0 in 2022, then surged by 305.26% to $77000.0 in 2023, then plunged by 77.92% to $17000.0 in 2024.
- The last three Other Accumulated Expenses figures came in at $17000.0 (Q4 2024), $77000.0 (Q4 2023), and $19000.0 (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Phio Pharmaceuticals | 13.77 Mn | 13.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 17,000.00 |
| Dec 31, 2023 | 77,000.00 |
| Dec 31, 2022 | 19,000.00 |
| Dec 31, 2020 | 104,000.00 |
| Dec 31, 2019 | 27,000.00 |
| Dec 31, 2017 | 8,000.00 |
| Dec 31, 2016 | 10,000.00 |
| Dec 31, 2015 | 10,000.00 |
| Dec 31, 2014 | 5,000.00 |
| Dec 31, 2013 | 183,000.00 |
| Dec 31, 2012 | 256,000.00 |
| Dec 31, 2011 | 93,000.00 |